TD Cowen Rates HCA Healthcare (HCA) buy, $431 Price Target
TD Cowen maintains its buy rating on HCA Healthcare with a $431 price target, a 11.63% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
TD Cowen rated HCA Healthcare, Inc. ($HCA) "buy" with a $431 price target on June 22, 2026.
Since the rating, $HCA is up 4.1% after 1 week, down 1.4% after 1 month and up 21.9% to date (from the $376.30 close on Jun 22, 2026).
HCA
HCA Healthcare, Inc.
Key Points
- TD Cowen reiterated its buy rating for HCA Healthcare, setting a price target of $431 on June 22, 2026.
- TD Cowen's $431 price target implies 11.63% upside from HCA Healthcare, Inc.'s ($HCA) current $386.09 share price.
- HCA shares traded around $374.95 on Monday, with a market cap of $83.2 billion and a P/E ratio of 12.92.
- Insider transactions include multiple buys by executives in late April and early May 2026.
Get $HCA trade alerts by text
We text you when insiders, Congress or big funds trade $HCA. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated HCA Healthcare, Inc. alert may contain errors. Disclosures
TD Cowen has reiterated its buy rating on HCA Healthcare, Inc. (NYSE:HCA), maintaining a price target of $431. This decision was announced on June 22, 2026, with analyst Ryan Langston affirming his positive outlook for the healthcare giant.
TD Cowen vs. the S&P 500
Hypothetical returns from TD Cowen's disclosed trades, not real profit or advice. How we model this.
HCA Healthcare, Inc. Stock Down 9.7%
Shares of NYSE:HCA traded near $374.95 on Monday. HCA Healthcare boasts a market cap of approximately $83.2 billion. The stock has a P/E ratio of 12.92 and a forward P/E of 11.33. It has a 52-week low of $330.00 and a high of $556.52, with a 50-day moving average of $421.47 and a 200-day moving average of $460.57. The company has a current ratio of 0.83 and a quick ratio of 0.64.
$HCA price target
HCA Healthcare, Inc. daily closes and this analyst's $431 target. Not advice.
Recent Earnings
HCA Healthcare reported revenue of $76.39 billion, reflecting a growth rate of 4.3%. The company's net margin stands at 8.89%, with earnings per share (EPS) of $29.04. The next earnings report is expected on July 24, 2026.
Insider Buying and Selling at HCA Healthcare, Inc.
Recent insider activity includes several transactions on April 28, 2026, where executives such as William Frist, Hugh Johnston, Michael Michelson, and Wayne Joseph Riley purchased shares. Additionally, on May 7, 2026, EVP and CFO Mike Marks both sold and bought 3,336 shares.
Analysts Set New Price Targets
On June 22, 2026, TD Cowen maintained its buy rating for HCA Healthcare with a $431 price target. Earlier, on June 4, 2026, Bernstein maintained a hold rating with a $413 target. In April, several firms including Barclays and RBC Capital also sustained their buy ratings with targets ranging from $496 to $534.
About HCA Healthcare
HCA Healthcare, Inc. operates a comprehensive network of healthcare facilities across the United States. Based in Nashville, Tennessee, and led by CEO Samuel N. Hazen, the company manages a diverse array of hospitals, clinics, and specialized care centers. With about 230,000 employees, HCA provides a wide range of services, from emergency and surgical care to outpatient and therapeutic services.
Bottom Line
TD Cowen's reaffirmation of its buy rating for HCA Healthcare underscores confidence in the company's performance and future prospects. Investors track these ratings closely as they reflect expert analysis and market sentiment. As always, it's important to remember that analyst ratings are just one piece of the investment puzzle.
Related Filing Alerts
Source: TD Cowen's rating change on $HCA (Jun 22, 2026). Written by software, not financial advice. How we make alerts